WO2021249608A3 - A novel medicament for immune modulation and treating chronic or hyper inflammation - Google Patents

A novel medicament for immune modulation and treating chronic or hyper inflammation Download PDF

Info

Publication number
WO2021249608A3
WO2021249608A3 PCT/EG2021/000016 EG2021000016W WO2021249608A3 WO 2021249608 A3 WO2021249608 A3 WO 2021249608A3 EG 2021000016 W EG2021000016 W EG 2021000016W WO 2021249608 A3 WO2021249608 A3 WO 2021249608A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating chronic
immune modulation
development
novel medicament
diabetes type
Prior art date
Application number
PCT/EG2021/000016
Other languages
French (fr)
Other versions
WO2021249608A2 (en
WO2021249608A4 (en
Inventor
Mohamed Fadly Abd el Ghany ELKAZAZ
Original Assignee
Elkazaz Mohamed Fadly Abd El Ghany
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elkazaz Mohamed Fadly Abd El Ghany filed Critical Elkazaz Mohamed Fadly Abd El Ghany
Priority to AU2021286756A priority Critical patent/AU2021286756A1/en
Priority to GB2300774.3A priority patent/GB2612481A/en
Publication of WO2021249608A2 publication Critical patent/WO2021249608A2/en
Publication of WO2021249608A3 publication Critical patent/WO2021249608A3/en
Publication of WO2021249608A4 publication Critical patent/WO2021249608A4/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Present invention is a designation of a novel medicament for immune modulation and treating chronic or hyper inflammation. Its active ingredient is anabasine or its salt. It was designed for example to treat some of auto immune diseases permanently such as asthma and atopic dermatitis by one medication course, to stop the progression and development of diabetes type 2 in diabetics and restoring their blood sugar to normal with respect to administration in the disease early stages, to prevent the incidence and development of autoimmune Diabetes Type 1 resulted from T cell-mediated damage of pancreatic β-cells and loss of insulin production. Further, it plays a pivotal and protective role in treating hazardous infections caused by diverse pathogens to promote and accelerate recovery, including COVID -19 with its variants.
PCT/EG2021/000016 2020-06-09 2021-06-07 A novel medicament for immune modulation and treating chronic or hyper inflammation WO2021249608A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2021286756A AU2021286756A1 (en) 2020-06-09 2021-06-07 A novel medicament for immune modulation and treating chronic or hyper inflammation
GB2300774.3A GB2612481A (en) 2020-06-09 2021-06-07 A novel medicament for immune modulation and treating chronic or hyper inflammation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EG2020060768 2020-06-09
EG2020060768 2020-06-09

Publications (3)

Publication Number Publication Date
WO2021249608A2 WO2021249608A2 (en) 2021-12-16
WO2021249608A3 true WO2021249608A3 (en) 2022-02-03
WO2021249608A4 WO2021249608A4 (en) 2022-04-07

Family

ID=78845336

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EG2021/000016 WO2021249608A2 (en) 2020-06-09 2021-06-07 A novel medicament for immune modulation and treating chronic or hyper inflammation

Country Status (3)

Country Link
AU (1) AU2021286756A1 (en)
GB (1) GB2612481A (en)
WO (1) WO2021249608A2 (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741802A (en) * 1992-08-31 1998-04-21 University Of Florida Anabaseine derivatives useful in the treatment of degenerative diseases of the nervous system
WO1999010338A2 (en) * 1997-08-29 1999-03-04 University Of Florida Benzylidene- and cinnamylidene-anabaseines as neuronal nicotinic alpha-7 receptor agonists
US20050288333A1 (en) * 2004-06-08 2005-12-29 Kem William R Controlling angiogenesis with anabaseine analogs
US20070232651A1 (en) * 2006-01-26 2007-10-04 Habgood Gregory J Novel anabaseine derivatives, pharmaceutical compositions and methods of use thereof
US9387201B2 (en) * 2011-08-29 2016-07-12 Rcp Development, Inc. Methods of providing anti-inflammation support
US20180139961A1 (en) * 2016-11-20 2018-05-24 Iowa State University Research Foundation, Inc. (s)-5-ethynyl-anabasine, derivatives thereof, and related compositions and methods of making and using
WO2019202396A1 (en) * 2018-04-16 2019-10-24 Poviva Tea, Llc Compositions infused with nicotine compounds and methods of use thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741802A (en) * 1992-08-31 1998-04-21 University Of Florida Anabaseine derivatives useful in the treatment of degenerative diseases of the nervous system
WO1999010338A2 (en) * 1997-08-29 1999-03-04 University Of Florida Benzylidene- and cinnamylidene-anabaseines as neuronal nicotinic alpha-7 receptor agonists
US20050288333A1 (en) * 2004-06-08 2005-12-29 Kem William R Controlling angiogenesis with anabaseine analogs
US20070232651A1 (en) * 2006-01-26 2007-10-04 Habgood Gregory J Novel anabaseine derivatives, pharmaceutical compositions and methods of use thereof
US9387201B2 (en) * 2011-08-29 2016-07-12 Rcp Development, Inc. Methods of providing anti-inflammation support
US20180139961A1 (en) * 2016-11-20 2018-05-24 Iowa State University Research Foundation, Inc. (s)-5-ethynyl-anabasine, derivatives thereof, and related compositions and methods of making and using
WO2019202396A1 (en) * 2018-04-16 2019-10-24 Poviva Tea, Llc Compositions infused with nicotine compounds and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHOLINERGIC EFFECTIVENESS OF ANABASINE DERIVATIVES N. YA. LUKOMSKAYA ET AL.: "I. M. Sechenov Institute of Evolutionary Physiology and Biochemistry, Academy of Sciences of the USSR, Leningrad", INSTITUTE OF NATIONAL ECONOMY, TASHKENT. TRANSLATED FROM KHIMIKO-FARMATSEVTICHESKII ZHUMAL, vol. 24, no. 7, July 1990 (1990-07-01), pages 48 - 50 *
E. SHULTSA ET AL.: "Anabasine as a Precursor for the Synthesis of Potential Agonists of Neuronal Acetylcholine Receptors E.", DOKLADY CHEMISTRY, vol. 413, 2007, pages 59 - 63, XP055903371, ISSN: 0012-5008 *

Also Published As

Publication number Publication date
AU2021286756A1 (en) 2023-03-23
WO2021249608A2 (en) 2021-12-16
GB202300774D0 (en) 2023-03-08
WO2021249608A4 (en) 2022-04-07
GB2612481A (en) 2023-05-03

Similar Documents

Publication Publication Date Title
Ratner et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre‐planned meta‐analysis of phase 3 trials
TN2016000500A1 (en) Composition for Treating Diabetes Comprising Long-acting lnsulin Analogue Conjugale and Long-acting lnsulinotropic Peptide Conjugale
WO2012055967A3 (en) Treating diabetes melitus using insulin injections administered with varying injection intervals
Mantadakis et al. Intravenous iron sucrose for children with iron deficiency anemia: a single institution study
Luo et al. Use of Ophiocordyceps sinensis (syn. Cordyceps sinensis) combined with angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB) versus ACEI/ARB alone in the treatment of diabetic kidney disease: a meta-analysis
JP2020502150A5 (en)
WO2016060517A3 (en) Composite preparation, containing novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative and another active ingredient, for preventing or treating metabolic diseases
WO2013109342A8 (en) Method of treating diabetes using non-glycosylated apolipoprotein a-iv
Enginyurt et al. The role of pure honey in the treatment of diabetes mellitus
WO2021249608A3 (en) A novel medicament for immune modulation and treating chronic or hyper inflammation
Fucci-da-Costa et al. Drug delivery after microneedling: report of an adverse reaction
MY197721A (en) Composition and uses thereof
Mishra et al. Effect of Tinospora cordifolia as an add-on therapy on the blood glucose levels of patients with Type 2 diabetes.
Hussien et al. Effect of atorvastatin and garlic on lipid profile in hyperlipidemic patients
Kularatne et al. Safety and efficacy of subcutaneous adrenaline as a treatment for anaphylactic reactions to polyvalent antivenom
Schellong et al. Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient: an analysis of the CERTIFY study
Shojaei et al. Ephedraceae as a treatment for hyperlipidemia and hyperglycemia: an experimental study
Calderon et al. Sublingual allergen immunotherapy in children: An evidence-based overview
Terada et al. The anti-inflammatory effect of 0.1% bromfenac and 0.1% betamethasone combination in post-cataract surgery patients with diabetes mellitus
Sequeira et al. What’s Eating You? Dusky Pigmy Rattlesnake Envenomation and Management
Yan Wheals: case report
Lagutkina et al. Role of pharmaceutical information in formation of competent consumer behaviour in the pharmaceutical market
이윤호 et al. Meta-Analytic Comparison of Peripheral Endovascular Intervention Methods for Femoropopliteal Disease
Mant et al. Active BP management is more important than the specific SBP target in stroke patients
Joshi One Year Post-marketing Surveillance Study of Saroglitazar in Patients with Diabetic Dyslipidemia and History of Coronary Heart Disease

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 202300774

Country of ref document: GB

Kind code of ref document: A

Free format text: PCT FILING DATE = 20210607

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021286756

Country of ref document: AU

Date of ref document: 20210607

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 21822192

Country of ref document: EP

Kind code of ref document: A2